CTLA4 and neoplasm: In germ free mice bearing MC38 tumors (murine colorectal carcinoma cell line), the administration of inosine, CpG as a costimulator, and anti-CTLA-4 therapy experienced a significant reduction in tumor burden, demonstrating the ability of microbiome-derived metabolites to potentiate the response to immune checkpoint blockade therapy [46].